Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

AGNC (AGNC) Q2 2025 Earnings Call Transcript

View original at finance.yahoo.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, July 22, 2025 at 8:30 a.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GSE reform will follow a do-no-harm approach with no upward pressure on mortgage rates

    80% confidence
  • AGNC has no plans to grow for the sake of growing; growth is tied to accretive capital raising

    80% confidence
  • Net spread and dollar roll income expected in range of mid- to high $0.30s to low to mid-$0.40s per share

    80% confidence
  • AGNC has the lowest operating costs in the industry at 111 basis points

    80% confidence
  • Marginal investments are expected to generate high teens returns, somewhere between 18% to 20%

    80% confidence
  • Federal Reserve quantitative tightening expected to end relatively soon, possibly through year-end 2025

    80% confidence
  • The U.S. government will maintain implicit guarantees for Fannie Mae and Freddie Mac during privatization

    80% confidence
  • The outlook improved in Q2 2025 due to manageable MBS supply, growing MBS demand, stabilizing spreads at cheap levels, and cautious GSE reform approach

    80% confidence
  • Expected MBS net supply for 2025 is approximately $200 billion at the low end of forecasts

    80% confidence
  • GSE privatization must not widen mortgage spreads and should potentially tighten them

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript — Source | Via News | ViaNews EU